Srivastava Sapna 4

What Happened

• Sapna Srivastava, a director of Aura Biosciences (AURA), was granted a total of 45,000 award units on June 11, 2026: 15,000 restricted stock units (RSUs) and a 30,000-unit derivative award described as a stock option. Both awards were reported at $0.00 per share (no cash paid) and thus have no immediate out-of-pocket value to the reporting person.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the standard two-business-day window).
• Awards: 15,000 RSUs (F1) and 30,000 stock-option-style awards (derivative) (F2); reported acquisition price $0.00 for each.
• Vesting: Both awards vest in full upon the earlier of (a) June 11, 2027 or (b) the next annual meeting of stockholders, subject to continued service by the reporting person.
• Shares owned after the transaction: Not reported in the supplied data.
• No 10b5-1 plan, tax-withholding sale, or immediate exercise/sale was indicated in the filing.

Context

• RSUs are a form of equity compensation that convert to common shares upon vesting; the 30,000-unit derivative award is described as a stock option that will vest and become exercisable on the same schedule. These are grants/compensation events, not open-market purchases or sales, and therefore do not reflect an immediate cash investment or divestment by the director.
• For retail investors: awards are common for directors and executives and are often part of compensation/retention. They provide potential future upside if the company performs well, but they are subject to the stated vesting conditions and do not necessarily signal the director’s near-term sentiment.